Holen Sie sich die Stockscreener-App
17.83
0.89%
-0.16
Handel nachbörslich:
17.85
0.02
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$17.99
Offen:
$17.63
24-Stunden-Volumen:
1.85M
Relative Volume:
2.62
Marktkapitalisierung:
$1.62B
Einnahmen:
$802.20M
Nettoeinkommen (Verlust:
$-155.20M
KGV:
-5.3065
EPS:
-3.36
Netto-Cashflow:
$-141.30M
1W Leistung:
-18.81%
1M Leistung:
-32.64%
6M Leistung:
-8.42%
1J Leistung:
+4.76%
1-Tages-Spanne:
$16.87
$18.17
1-Wochen-Bereich:
$16.86
$22.91
52-Wochen-Spanne:
$15.99
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
UnitedHealthcare limits coverage for Myriad's GeneSight test - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire
Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%Here's Why - MarketBeat
Myriad Genetics Inc (MYGN) Trading Down 3.81% on Nov 4 - GuruFocus.com
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight - MarketWatch
UnitedHealthcare limits coverage for Myriad's GeneSight test By Investing.com - Investing.com UK
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing - GlobeNewswire
Trading (MYGN) With Integrated Risk Controls - Stock Traders Daily
Myriad weakness due to UnitedHealth coverage update, says Stephens - Yahoo Finance
Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge - Simply Wall St
Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment? - Simply Wall St
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes - MarketWatch
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - Seeking Alpha
Myriad Genetics (NASDAQ:MYGN) Shares Gap DownWhat's Next? - MarketBeat
Myriad Genetics (MYGN) to Release Quarterly Earnings on Thursday - MarketBeat
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Reduces Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Myriad Genetics 2008A Retrospective - RTTNews
Myriad Genetics Q4 Profit Declines, Yet Tops EstimateUpdate - RTTNews
Myriad Genetics Swings to Q3 Profit - RTTNews
Myriad Genetics Q1 Profit More Than Doubles, Yet Misses Estimate - RTTNews
Making Peace With Rivals For A Slice Of BRCA... - RTTNews
Relationship Tests Market Size 2024: Industry Overview, - openPR
What We Don’t Know Can Hurt: New Survey Reveals Knowledge Gaps About Breast Density and Cancer Risk - North American Precis Syndicate, Inc.
(MYGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Myriad: Q2 Earnings Snapshot - Barchart
Myriad Genetics Shares Fall Despite Partnership With jscreen - Yahoo Finance
OmniStar Financial Group Inc. Makes New $863,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Direct-To-Consumer Genetic Testing Market to Grow by USD 1.22 Billion from 2024-2028, Driven by Early Disease Diagnosis and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Myriad Genetics partners with jscreen for genetic testing By Investing.com - Investing.com Australia
Myriad Genetics partners with jscreen for genetic testing - Investing.com
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access - GlobeNewswire
21,968 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Sanctuary Advisors LLC - MarketBeat
Myriad's MyRisk test integrated into Flatiron's OncoEMR - Investing.com
Myriad's MyRisk test integrated into Flatiron's OncoEMR By Investing.com - Investing.com Canada
Myriad Genetics and Flatiron Health Partner to Make Genetic - GlobeNewswire
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration - StockTitan
Cancer Genomic Testing Market – 37% of Growth to Originate from APAC -Myriad Genetics, Centogene AG, Color Genomics, Que – IndiaPolitics.com - IndiaPolitics.com
Scotiabank reiterates positive outlook on Myriad Genetics shares By Investing.com - Investing.com UK
SG Americas Securities LLC Takes $649,000 Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Global Consumer Genomics Market Huge Growth in Future Scope - openPR
Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week - Yahoo Finance
Brokers Offer Predictions for Myriad Genetics, Inc.'s Q1 2025 Earnings (NASDAQ:MYGN) - MarketBeat
Learn to Evaluate (MYGN) using the Charts - Stock Traders Daily
Myriad Genetics, Inc. (NASDAQ:MYGN) CEO Sells 15,000 Shares - MarketBeat
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) - GuruFocus.com
Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock By Investing.com - Investing.com South Africa
Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock - Investing.com
Insiders At Myriad Genetics Sold US$6.5m In Stock, Alluding To Potential Weakness - Simply Wall St
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.73%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):